CD274 and cancer: The development of subclones and the reported changes in mutational signature, TMB and PD-L1 expression induced by treatment are clinically relevant as they might indicate a change in the signalling pathways and driver mutations, thus potentially altering the immune environment and the response to cancer therapy.